Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
As an investigational triple-receptor agonist targeting the GLP-1, GIP, and glucagon receptors, it is being studied in metabolic and weight-loss research contexts
Aldea, M
Now with a looming ban, many of the patients having success losing weight or treating their diabetes on both brand name and compounded medications will suffer if supply is not improved
Back to Research Hub Tip: The Research Hub is your starting point to browse all topics and connect the dots between compounds.
A 2024 study reported attenuated efficacy of GLP-1 RAs in individuals with obesity associated with pathogenic mutations or type 1 diabetes [134]
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
